PODD•Insulet targets a 2028 launch of fully closed-loop automated insulin delivery for type 2 diabetes, following a 2027 regulatory filing. It cites an addressable market above $30 billion and 2025 revenue of $2.7 billion.
Insulet targets a 2028 launch of fully closed-loop automated insulin delivery for type 2 diabetes and a regulatory filing in 2027. It targets U.S. type 2 diabetes market penetration of 10% to 15% by 2028, versus about 5% today, and projects U.S. type 1 diabetes penetration of 50% to 55%, versus about 40%. The company puts the addressable market above $30 billion and says the automated insulin delivery market could reach about $9 billion by 2028. Revenue was $2.7 billion in 2025, with an adjusted operating margin of 17.6%.
